Our partner

Image result for lilly logo

Sigilon is proud to partner with Eli Lilly and Company, a worldwide leader in diabetes care, to develop Shielded Living Therapeutics™ for the potential treatment of type 1 diabetes.

Under the terms of the agreement announced in April 2018, Lilly receives an exclusive worldwide license to Sigilon’s Afibromer™ technology for islet cell encapsulation. Sigilon received an upfront payment of over $75 million and is also eligible to receive up to $410 million in development and commercialization milestones, as well as single to double digit tiered royalties on future product sales should the collaboration yield a commercially successful product.

Our investor

 

We are pleased to have Flagship Pioneering as our founding investor. Flagship Pioneering conceives, creates, resources and develops first-in-category life sciences companies. The firm has founded and funded some of the most innovative companies in biotechnology over the last two decades. To learn more please visit flagshippioneering.com

Partner with us

We are interested in exploring strategic partnerships that contribute expertise, resources, geographic reach and/or disease area knowledge to our platform.

Our main focus is developing proprietary therapeutics. However, there are also high value partnership opportunities in diverse life sciences applications for our proprietary library of Afibrotek™ compounds.

If you would like to learn more, please contact:
Anne Altmeyer
Chief Business Officer
busdev@sigilon.com

Areas of partnering interest include:

  • Blood, lysosomal storage and metabolic disorders and other serious chronic diseases
  • Partner targets/programs which, when combined with our cell engineering and Afibromer™ platform, could become new, living therapeutics to address a wide range of protein deficiency disorders
  • We are interested in next generation approaches to treating diseases utilizing the latest capabilities of synthetic biology – including novel programmable treatments
  • Applications of Sigilon’s Afibrotek™ platform to avoid the problems of foreign body response on a wide variety of biomaterials